Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1503 - Comparison of oxaliplatin-related spleen enlargement in patient with gastric cancer who received S-1 versus capecitabine as a combination partner of oxaliplatin


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Gastric Cancer


Seyoung Seo


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


S. Seo1, M. Kim1, M.J. Kim2, M. Kim3, Y.I. Park3, S.R. Park1

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Center For Colorectal Cancer, Research Institute and Hospital, National Cancer Center, 10408 - Goyang/KR
  • 3 Center For Gastric Cancer, Research Institute and Hospital, National Cancer Center, 10408 - Goyang/KR


Abstract 1503


Oxaliplatin (OX)-based chemotherapy is known to cause hepatic sinusoidal injury, resulting portal hypertension with splenomegaly (SM). We compared this OX-induced hepatopathy, SM, and their clinical significance according to combined oral fluoropyrimidines, S-1 vs. capecitabine (X) in gastric cancer (GC).


We analyzed pts from two prospective trials for GC, adjuvant XELOX (X 1000 mg/m2 bid on D1-14 + OX 130 mg/m2 on D1 q3w, 8 cycles; n = 52) and palliative SOX (S-1 40 mg/m2 bid on D1-14 + OX 130 mg/m2 on D1 q3w, continuous [SOX-c, n = 52] vs. intermittent [SOX-i, discontinuing after 6th and restarting on progression, n = 53]) Spleen volume (vol) was retrospectively measured by Rapidia software.


Baseline sex, age, ECOG PS, BSA, spleen vol, levels of platelet (plt)/liver enzyme/bilirubin (bil) and OX cumulative dose during 8 cycles did not differ in XELOX and SOX-c. After 8 cycles, the SOX-c had more SM, hepatic enhancing heterogeneity, hyper-bil, and thrombocytopenia than the XELOX (Table). The SOX-c was a risk factor for developing SM (adjusted odds ratio, 4.7; 95% CI, 2.0-10.8; p


S-1 seems to enhance OX-induced hepatic sinusoidal injuries than capecitabine in pts with GC with clinical significance of higher incidences of splenomegaly, thrombocytopenia, and hyperbilirubinemia.

Clinical trial identification

Legal entity responsible for the study

Sook Ryun Park




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.